Evidence Generation Is the Foundation to Optimal Product Positioning
HDMA seeks to encourage more outreach to business partners and government
A look into the growing compliance risks associated with patient services
New technological capabilities will enable management of sample-distribution processes to keep up with a challenging environment
Addressing patient recruitment and retention issues is a natural role for CTEs
The 7th Annual Model N survey shows that industry is struggling with the growing complexity of contracts and pricing for managed care and government programs
Industry anticipates meaningful guidance from FDA on use of social media
A review of 84 branded pharmaceutical products with changed ownership as of 2005 shows that many of them can continue to sell, often with much higher prices By Albert I. Wertheimer, PhD, MBA, Temple University, and Ellen F. Loh, BS, MBA, University of Maryland, Baltimore
Vaccine administration is shifting from multidose vials to prefilled syringes for a host of important safety and economic considerations
Internal compliance reviews are not enough; life sciences companies need to assess their third-party business partners
Combining high-quality patient-support services with comprehensive and continually updated analytics results in better outcomes
Elaborate testing is necessary to ensure the stability and functionality of today's drug-delivery systems
The pharma industry needs to go farther in adapting to new marketplace realities
A 'performance curve' chart for containers could simplify the design process
Modernized packaging technologies can change the drug-distribution dynamic - and improve overall healthcare
With a number of vaccine trials progressing globally, recent data loss and quality control errors have raised the importance of ensuring effective data systems in this effort
Hubs and other patient services need to stress the personal
While the pharma industry is growing more dependent on companion diagnostics, test developers face an uncertain business model
Both pharmacological and economic factors drive the decision to use these technologies